Abstract
PURPOSE: To compare the cost-effectiveness of (99m)Tc-methoxyisobutylisonitrile (MIBI) thyroid scintigraphy and the Afirma gene expression classifier for the assessment of cytologically indeterminate thyroid nodules. METHODS: A decision tree model was used. Costs were calculated from the perspective of the German health insurance system. The robustness of the results was assessed with probabilistic sensitivity analyses using a Monte Carlo simulation. RESULTS: Life expectancy was 34.3 years (estimated costs per patient euro1,459 - euro2,224) for the MIBI scan and 34.1 years (estimated costs euro3,560 - euro4,071) for the molecular test. These results were confirmed by the Monte Carlo simulation. CONCLUSION: MIBI thyroid scintigraphy is more cost-effective than the gene expression classifier.
Original language | English |
---|---|
Pages (from-to) | 1497-1500 |
Number of pages | 4 |
Journal | European Journal of Nuclear Medicine and Molecular Imaging |
Volume | 41 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 2014 |
Keywords
- Tc-99m-Methoxyisobutylisonitrile (MIBI)
- Thyroid nodule
- Afirma (R) gene expression classifier
- Cost-effectiveness
- ASPIRATION-CYTOLOGY
- MALIGNANCY
- SCINTIGRAPHY
- TC-99M-MIBI